Titan Medical Common Stock to Trade on Nasdaq

TORONTO, June 27, 2018 (GLOBE NEWSWIRE) -- Titan Medical Inc. (“Titan” or the “Company”)(TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), today announced that shares of its common stock were approved for listing on the Nasdaq Capital Market. Titan Medical’s common stock will commence trading on the Nasdaq Capital Market on June 27, 2018 under the symbol TMDI.

Titan Medical’s common stock will continue to trade uninterrupted on the Toronto Stock Exchange (TSX) under the symbol TMD.  Previously Titan Medical’s common stock traded on the OTC market under the symbols TITXF and TITXD.

“We are pleased to achieve this significant milestone and look forward to shares of our common stock trading on Nasdaq,” said David McNally, CEO of Titan Medical. “As a dual-listed company on both Nasdaq and the Toronto Stock Exchange, we have the opportunity to broaden our exposure to U.S. institutional investors, diversify our shareholder base, expand our access to capital and increase liquidity.”

About Titan Medical Inc.

Titan Medical Inc. is focused on research and development through to the planned commercialization of computer-assisted robotic surgical technologies for application in minimally invasive surgery. The Company is developing the SPORT Surgical System, a single-port robotic surgical system. The SPORT Surgical System is comprised of a surgeon-controlled patient cart that includes a 3D high-definition vision system and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body. Titan intends to initially pursue focused surgical indications for the SPORT Surgical System, which may include one or more of gynecologic, urologic, colorectal or general abdominal procedures.

For more information, please visit the Company’s website at www.titanmedicalinc.com.

Forward-Looking Statements

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the “Risk Factors” section of the Company’s Annual Information Form dated March 31, 2018 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Contacts:

LHA Investor Relations
Kim Sutton Golodetz
(212) 838-3777
kgolodetz@lhai.com
   or
Bruce Voss
(310) 691-7100
bvoss@lhai.com

© 2018 GlobeNewswire, Inc. All Rights Reserved.